LONDON, Oct. 5 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKPLSE: Nasdaq:LSE:SKYE) announces today that its R&D Day meetings, originally intended to be held in London on 26 October and in New York on 27 October, are being rescheduled because of certain restrictions imposed by the Rights Issue announced on 28 September. The London meeting will now be held on Wednesday 25 January 2006 at The Brewery, Chiswell St, London and will start at 0930. The New York meeting will be held on Thursday 26 January at the St Regis Hotel, 2 East 55th Street, New York and will take place over lunch. Attendance is by invitation only but the meetings will be webcast. Further details of the agenda for these meetings will be published nearer the day. These meetings will provide an opportunity to gain an in-depth awareness and understanding of key products in our portfolio and pipeline and to meet members of our senior management team. For further information please contact: SkyePharma PLC +44 207 491 1777 Michael Ashton, Chief Executive Officer Peter Laing, Director of Corporate Communications +44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000 Tim Anderson / Mark Court / Rebecca Skye Dietrich About SkyePharma SkyePharma develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now eleven approved and marketed products incorporating SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit http://www.skyepharma.com/. The securities to be issued in the Rights Issue have not been and will not be registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an appropriate exemption from registration requirements. DATASOURCE: SkyePharma PLC CONTACT: Michael Ashton, Chief Executive Officer, +44-207-491-1777, or Peter Laing, Director of Corporate Communications, +44-207-491-5124, or Sandra Haughton, US Investor Relations, +1-212-753-5780, all of SkyePharma PLC; or Tim Anderson, or Mark Court, or Rebecca Skye Dietrich, all of Buchanan Communications, +44-207-466-5000 Web site: http://www.skyepharma.com/

Copyright